Evidence map›Paper›PMID 15313882›Full record

ArticleBritish journal of pharmacology2004

Role of PDE4 in superoxide anion generation through p44/42MAPK regulation: a cAMP and a PKA-independent mechanism.

Claire Jacob, Corinne Szilagyi, Janet M Allen, Claude Bertrand, Vincent Lagente

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 29 citations in OpenAlex.

  1. Targeting neutrophils for cancer therapy.Nature reviews. Drug discovery · 2025
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. A CaMKII/PDE4D negative feedback regulates cAMP signaling.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Claire JacobPfizer Global R&D, Fresnes Laboratories, Department of Biology, 3-9 rue de la Loge, 94265 Fresnes, France. cjacob@itsa.ucsf.edu
Corinne Szilagyi
Janet M Allen
Claude Bertrand
Vincent Lagente
Pfizer (France) · FRPfizer (United States) · USUniversité de Rennes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the generation of reactive oxygen species (ROS) from bronchoalveolar lavage (BAL) cells of either control or LPS-exposed rats and the effects of PDE4 inhibitors on ROS production. The PDE4 inhibitors, rolipram and Ariflo (cilomilast, SB 207499) dose-dependently (0.1-10 microm) inhibited fMLP-induced superoxide anion (O(2)(*-)) production (IC(50)s: 0.03 and 0.55 microm, respectively) in BAL cells of Wistar rats collected 3 h after an LPS-aerosol (200 micrograms ml(-1), 1 h). These BAL contained 85-95% neutrophils (BAL cells enriched in neutrophils). In contrast, BAL cells collected at the end of the challenge contained only macrophages and in these conditions, rolipram and Ariflo (0.1-10 microm) could only inhibit 25 and 45% of fMLP-induced O(2)(*-) release, respectively. We also observed that the inhibition of p44/42(MAPK) by PD98059 (1-10 microm) increased O(2)(*-) release by BAL cells enriched in neutrophils, but not by macrophages, and prevented the inhibition of O(2)(*-) production induced by PDE4 inhibitors. Western blot analysis showed that PDE4 inhibitors strongly activated p44/42(MAPK) in BAL cells enriched in neutrophils but not in macrophages. And in these cells, PDE4 and p44/42(MAPK) were co-immunoprecipitated by a polyclonal anti-PDE4 antibody. The following cell permeable-cAMP analogues, dbcAMP (10 microm-1 mm), 8-CPT-cAMP (1 mm) and 8-pMeOPT-2'-O-Me-cAMP (0.5 mm), could not reduce fMLP-induced O(2)(*-) production and both PKA inhibitors, PKA inhibitor 14-22 amide myristoylated (50 nm-1 microm) and H-89 (100 nm-1 microm), did not affect the decrease of O(2)(*-) release induced by PDE4 inhibitors in BAL cells enriched in neutrophils. These data suggest that PDE4 inhibitors decreased fMLP-induced O(2)(*-) release in BAL cells enriched in neutrophils but not in macrophages, through p44/42(MAPK) activation by a cAMP- and a PKA-independent mechanism.

Indexed as

3',5'-Cyclic-AMP PhosphodiesterasesAnimalsBronchoalveolar Lavage FluidBucladesineCREB-Binding ProteinCyclic AMPCyclic Nucleotide Phosphodiesterases, Type 4Cyclohexanecarboxylic AcidsFlavonoidsGene Expression Regulation, EnzymologicImidazolesLipopolysaccharidesMacrophagesMitogen-Activated Protein KinasesNeutrophilsN-Formylmethionine Leucyl-Phenylalanine2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one3',5'-Cyclic-AMP PhosphodiesterasesBucladesineCilomilastCREB-Binding ProteinCrebbp protein, ratCyclic AMPCyclic Nucleotide Phosphodiesterases, Type 4Cyclohexanecarboxylic AcidsFlavonoidsImidazolesLipopolysaccharidesMitogen-Activated Protein KinasesN-Formylmethionine Leucyl-PhenylalanineNitrilesNuclear Proteinsp38 Mitogen-Activated Protein KinasesProtein Kinase InhibitorsProto-Oncogene Proteins c-rafPyridinesReactive Oxygen SpeciesRolipramSB 203580SuperoxidesTrans-Activators

Identifiers

PMID15313882
PMCPMC1575336
OpenAlexW2002874752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.